It will also be important to examine the cancer-preventive effectiveness of combinations of FDA-approved agents at low concentrations of each class, including β-blockers, metformin, statins, and GLP-1 receptor agonists, and consider replacing first-generation β blockers with novel drugs (e.g., third-generation carvedilol). Here, GLP1R is linked to cancer.